Key facts
- This page summarizes Niall O'Donnell's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Nov 2022, 19:02.
Niall O'Donnell - 11 Nov 2022 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- Director
- Issuer ticker
- MIRM
- Reported as of
- 11 Nov 2022
- Net transaction value
- -$5,956,855
- SEC form
- 4
- Accepted by SEC
- 15 Nov 2022, 19:02:54 UTC
- Prior SEC filing
- 06 Jun 2022
- Next SEC filing
- 16 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Niall O'Donnell, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Niall O'Donnell filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 15 Nov 2022.
Change
- Previous filing in this sequence was filed on 06 Jun 2022.
- Current net transaction value: -$5,956,855.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRM
transaction
Common Stock
Sale
- Transaction value
- $3,481,410
- Shares
- -174,121
- Change %
- -9.1%
- Price
- $19.99
- Shares after
- 1,746,997
- Date
- 11 Nov 2022
- Ownership
- By RiverVest Venture Fund IV, L.P.
- Footnotes
- F1, F2
MIRM
transaction
Common Stock
Sale
- Transaction value
- $629,423
- Shares
- -32,109
- Change %
- -1.8%
- Price
- $19.60
- Shares after
- 1,714,888
- Date
- 14 Nov 2022
- Ownership
- By RiverVest Venture Fund IV, L.P.
- Footnotes
- F2, F3
MIRM
transaction
Common Stock
Sale
- Transaction value
- $1,846,022
- Shares
- -93,770
- Change %
- -5.5%
- Price
- $19.69
- Shares after
- 1,621,118
- Date
- 15 Nov 2022
- Ownership
- By RiverVest Venture Fund IV, L.P.
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.
Footnote F2
RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive.